The combination rifampin-nitazoxanide, but not rifampin-isoniazid-pyrazinamide-ethambutol, kills dormant mycobacterium tuberculosis in hypoxia at neutral pH

Angelo Iacobino, Federico Giannoni, Manuela Pardini, Giovanni Piccaro, Lanfranco Fattorini

Research output: Contribution to journalArticlepeer-review

Abstract

The activities of rifampin, nitazoxanide, PA-824, and sutezolid were tested against dormant Mycobacterium tuberculosis under conditions mimicking caseous granulomas (hypoxia at pH 7.3) in comparison with those of the combination rifampin-isoniazid-pyrazinamide-ethambutol (R-I-Z-E), which is used for human therapy. Mycobacterial viability was monitored by CFU and regrowth in MGIT 960. As shown by lack of regrowth in MGIT, rifampin-nitazoxanide-containing combinations, but not R-I-Z-E, killed dormant cells in 28 to 35 days. These observations might be important in designing new tuberculosis therapies.

Original languageEnglish
Article numbere00273-19
JournalAntimicrobial Agents and Chemotherapy
Volume63
Issue number7
DOIs
Publication statusPublished - 2019

Keywords

  • Hypoxia
  • Mycobacterium tuberculosis
  • Nitazoxanide
  • PH
  • Rifampin
  • Tuberculosis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'The combination rifampin-nitazoxanide, but not rifampin-isoniazid-pyrazinamide-ethambutol, kills dormant mycobacterium tuberculosis in hypoxia at neutral pH'. Together they form a unique fingerprint.

Cite this